



**ACGME International**

**Advanced Specialty Program Requirements for  
Graduate Medical Education in  
Medical Toxicology  
(Emergency Medicine, Preventive Medicine)**

Initial Approval:

1 **ACGME International Specialty Program Requirements for**  
2 **Graduate Medical Education**  
3 **in Medical Toxicology (Emergency Medicine, Preventive Medicine)**  
4

5 **Int. Introduction**  
6

7 *Background and Intent: Programs must achieve and maintain Foundational Accreditation*  
8 *according to the ACGME-I Foundational Requirements prior to receiving Advanced Specialty*  
9 *Accreditation. The Advanced Specialty Requirements noted below complement the ACGME-*  
10 *I Foundational Requirements. For each section, the Advanced Specialty Requirements*  
11 *should be considered together with the Foundational Requirements.*  
12

13 **Int. I. Definition and Scope of the Specialty**  
14

15 Medical toxicology is a clinical specialty that includes the monitoring, prevention,  
16 evaluation, and treatment, in all age groups, of injury and illness due to occupational  
17 and environmental exposures, pharmaceutical agents, and unintentional and  
18 intentional poisoning. A medical toxicology fellowship provides fellows with experience  
19 in the clinical practice of medical toxicology and prepares physicians as practitioners,  
20 educators, researchers, and administrators capable of practicing medical toxicology in  
21 academic and clinical settings.  
22

23 **Int. II. Duration of Education**  
24

25 Int. II.A. The educational program in medical toxicology must be 24 or 36 months in  
26 length.  
27

28 **I. Institution**  
29

30 **I.A. Sponsoring Institution**  
31

32 I.A.1. A fellowship in medical toxicology must function as an integral part of an ACGME-I-  
33 accredited residency in emergency medicine or preventive medicine.  
34

35 **I.B. Participating Sites**  
36

37 I.B.1. Any medical toxicology experience not available at the primary clinical site or  
38 Sponsoring Institution must be provided through an affiliation with a participating  
39 site.  
40

41 I.B.2. Programs using multiple participating sites must ensure the provision of a unified  
42 educational experience for the fellows.  
43

44 I.B.3. The primary clinical site must be a primary hospital or a poison center.  
45

46 I.B.3.a) If the primary clinical site is a poison center, the program must identify a  
47 hospital where the clinical experience will take place.  
48

49 I.B.4. Participating sites, including a poison center, should be in close physical proximity  
50 to the primary clinical site unless they provide special resources that are not  
51 available at the primary clinical site.  
52

53	<b>II.</b>	<b>Program Personnel and Resources</b>
54		
55	<b>II.A.</b>	<b>Program Director</b>
56		
57	II.A.1.	The program director must have at least three years of documented educational and/or administrative leadership in an emergency medicine, pediatrics, or preventive medicine residency or in a medical toxicology fellowship.
58		
59		
60		
61	II.A.2.	The program director must have current clinical activity in the practice of medical toxicology.
62		
63		
64	II.A.3.	The program director must have academic involvement in scholarly activity in medical toxicology.
65		
66		
67	<b>II.B.</b>	<b>Faculty</b>
68		
69	II.B.1.	There must be a minimum of two medical toxicology core physician faculty members based at the primary clinical site, including the program director.
70		
71		
72	II.B.2.	Faculty members must supervise all fellows in their development of clinical, educational, research, advocacy, and administrative skills.
73		
74		
75	II.B.3.	Consultants from appropriate medical specialties must be available for consultation and didactic sessions, to include special expertise in:
76		
77		
78	II.B.3.a)	cardiovascular disease;
79		
80	II.B.3.b)	dermatology;
81		
82	II.B.3.c)	gastroenterology;
83		
84	II.B.3.d)	immunology;
85		
86	II.B.3.e)	nephrology;
87		
88	II.B.3.f)	ophthalmology;
89		
90	II.B.3.g)	pathology;
91		
92	II.B.3.h)	pulmonary disease; and,
93		
94	II.B.3.i)	surgical subspecialties.
95		
96	<b>II.C.</b>	<b>Other Program Personnel</b>
97		
98	II.C.1.	Consultants from appropriate non-medical specialties must be available for consultation and didactic sessions, to include:
99		
100		
101	II.C.1.a)	biostatistics;
102		
103	II.C.3.b)	botany;
104		

- 105 II.C.3.c) disaster and mass casualty incident management;  
 106  
 107 II.C.3.d) epidemiology;  
 108  
 109 II.C.3.e) environmental toxicology;  
 110  
 111 II.C.3.f) forensic toxicology;  
 112  
 113 II.C.3.g) hazardous materials;  
 114  
 115 II.C.3.h) herpetology;  
 116  
 117 II.C.3.i) industrial hygiene;  
 118  
 119 II.C.3.j) laboratory toxicology;  
 120  
 121 II.C.3.k) mycology;  
 122  
 123 II.C.3.l) occupational toxicology;  
 124  
 125 II.C.3.m) public health; and,  
 126  
 127 II.C.3.n) zoology.

128  
 129 **II.D. Resources**

- 130  
 131 II.D.1. There must be a poison control center or medical toxicology service that  
 132 annually has at least 1,500 encounters from the community that require medial  
 133 toxicologist consultation or intervention.  
 134  
 135 II.D.2. Resources must be available to support the provision of clinical experience in  
 136 adult and pediatric critical care areas.  
 137  
 138 II.D.3. The following must be available at the primary clinical site or at an affiliated  
 139 participating site:  
 140  
 141 II.D.3.b) adult and pediatric inpatient facilities;  
 142  
 143 II.D.3.c) adult and pediatric intensive care facilities;  
 144  
 145 II.D.3.d) adult and pediatric outpatient facilities;  
 146  
 147 II.D.3.e) emergency services for both adult and pediatric patients;  
 148  
 149 II.D.3.f) renal dialysis services with 24-hour availability; and,  
 150  
 151 II.D.3.g) toxicology laboratory services with 24-hour availability.  
 152  
 153 II.D.4. There should be an affiliation with a school of pharmacy or department of  
 154 pharmacology.  
 155  
 156 II.D.4.b) In the absence of an affiliation with a school of pharmacy or department

157		of pharmacy, a Doctor of Pharmacy or PhD pharmacologist should be
158		appointed to the teaching faculty.
159		
160	II.D.5.	There should be an affiliation with a school of public health, department of
161		health, department of population health, department of community health, or
162		similar institution to provide regular didactic experience and consultation to
163		fellows.
164		
165	<b>III. Fellow Appointment</b>	
166		
167	<b>III.A. Eligibility Criteria</b>	
168	III.A.1.	Prior to appointment in the program, fellows should have completed an
169		ACGME-I-accredited residency program or a residency program acceptable to
170		the Sponsoring Institution's Graduate Medical Education Committee.
171	<b>III.B. Number of Fellows</b>	
172		
173		See International Foundational Requirements, Section III.B.
174		
175	<b>IV. Specialty-Specific Educational Program</b>	
176		
177	<b>IV.A. ACGME-I Competencies</b>	
178		
179	IV.A.1.	The program must integrate the following ACGME-I Competencies into the
180		curriculum.
181		
182	IV.A.1.a)	Professionalism
183		
184	IV.A.1.a).(1)	Fellows must demonstrate a commitment to
185		professionalism and an adherence to ethical principles.
186		
187	IV.A.1.b)	Patient Care and Procedural Skills
188		
189	IV.A.1.b).(1)	Fellows must provide patient care that is compassionate,
190		appropriate, and effective for the treatment of health
191		problems and the promotion of health. Fellows must
192		demonstrate competence in:
193		
194	IV.A.1.b).(1).(a)	gathering accurate, essential information
195		in a timely manner;
196		
197	IV.A.1.b).(1).(b)	integrating information obtained from patient history,
198		physical examination, physiologic recordings, and test
199		results to arrive at an accurate assessment and
200		treatment plan;
201		
202	IV.A.1.b).(1).(c)	integrating relevant biological, psychosocial, social,
203		economic, ethnic, and familial factors into the
204		evaluation and treatment of their patients;
205		
206	IV.A.1.b).(1).(d)	planning and implementing therapeutic treatment,

207		including pharmaceutical, medical device, behavioral,
208		and surgical therapies;
209		
210	IV.A.1.b).(1).(e)	assessing toxicological exposures in occupational
211		evaluations;
212		
213	IV.A.1.b).(1).(f)	serving as the primary or consulting physician
214		responsible for providing direct/bedside patient
215		evaluation, management, screening, and preventive
216		services for toxicology patients;
217		
218	IV.A.1.b).(1).(g)	evaluating and managing patients with acute or
219		chronic workplace occupational and environmental
220		exposures, including responsibility for providing
221		patient and worksite evaluation, management,
222		exposure assessment and control, and preventive
223		services;
224		
225	IV.A.1.b).(1).(h)	evaluating workplace risks and hazards;
226		
227	IV.A.1.b).(1).(i)	managing the entire course of critically poisoned
228		patients broadly representative of society, either as
229		the primary physician or as a consultant;
230		
231	IV.A.1.b).(1).(j)	serving as the primary or consulting physician
232		responsible for providing direct/bedside patient
233		evaluation, management, screening, and preventive
234		services for acutely poisoned patients; and,
235		
236	IV.A.1.b).(1).(k)	consulting on calls from a referral population of
237		poisoned patients under the supervision of a physician
238		who is a medical toxicologist.
239		
240	IV.A.1.b).(5)	Fellows must be able to perform all medical, diagnostic, and
241		surgical procedures considered essential for the area of practice,
242		including demonstrating competence in interpreting the results of
243		diagnostic tests.
244		
245	IV.A.1.c)	Medical Knowledge
246		
247	IV.A.1.c).(1)	Fellows must demonstrate knowledge of established and
248		evolving biomedical clinical, epidemiological, and social-
249		behavioral sciences, as well as the application of this
250		knowledge to patient care. Fellows must demonstrate
251		knowledge of:
252		
253	IV.A.1.c).(1).(a)	major developments in the basic and clinical sciences
254		relating to medical toxicology, through application of this
255		knowledge in the care of their patients;
256		
257	IV.A.1.c).(1).(b)	indications, risks, and limitations for procedures, and
258		management of patients through application of this

259		knowledge in their care;
260		
261	IV.A.1.c).(1).(c)	therapeutic approaches, including resuscitation, initial management, pharmacological basis of antidote use, supportive and other care, and withdrawal syndrome management;
262		
263		
264		
265		
266	IV.A.1.c).(1).(d)	the basic and clinical sciences relating to medical toxicology;
267		
268		
269	IV.A.1.c).(1).(e)	biochemistry of metabolic processes, the pharmacology, pharmacokinetics, teratogenesis, toxicity, and interactions of therapeutic drugs;
270		
271		
272		
273	IV.A.1.c).(1).(f)	biochemistry of toxicants and toxins, kinetics, metabolism, mechanisms of acute and chronic injury, and carcinogenesis;
274		
275		
276		
277	IV.A.1.c).(1).(g)	clinical manifestations and differential diagnosis of poisoning from drugs; industrial, household, environmental, and natural products; and agents of bioterrorism toxicants;
278		
279		
280		
281		
282	IV.A.1.c).(1).(h)	analytical and forensic toxicology, including assay methods and interpretation;
283		
284		
285	IV.A.1.c).(1).(i)	laboratory and other diagnostic assessments, as well as forensics, medicolegal issues, and occupational drug test interpretation;
286		
287		
288		
289	IV.A.1.c).(1).(j)	assessment and population health, including criteria for causal inference, monitoring, occupational assessment and prevention, principles of epidemiology, and statistics;
290		
291		
292		
293	IV.A.1.c).(1).(k)	experimental design and statistical analysis of data as related to laboratory, clinical, and epidemiologic research;
294		
295		
296	IV.A.1.c).(1).(l)	occupational toxicology, including acute and chronic workplace exposure to intoxicants and basic concepts of workplace and industrial hygiene;
297		
298		
299		
300	IV.A.1.c).(1).(m)	prevention of poisoning, including prevention of occupational exposures by intervention methodologies that take into account the epidemiology, environmental factors, and the role of regulation and legislation in prevention;
301		
302		
303		
304		
305		
306	IV.A.1.c).(1).(n)	environmental toxicology, including identification of hazardous materials and the basic principles of management of large-scale environmental contamination and mass exposures;
307		
308		
309		
310		

311	IV.A.1.c).(1).(o)	function, management, and financing of poison centers;
312		
313	IV.A.1.c).(1).(p)	the role of regional poison centers in response to
314		hazardous materials incidents, including terrorism, risk
315		assessment, and communication;
316		
317	IV.A.1.c).(1).(q)	oral and written communication skills, including risk
318		communication and teaching techniques;
319		
320	IV.A.1.c).(1).(r)	economics of health care and current health care
321		management issues, including cost-effective patient care,
322		quality improvement, resource allocation, and clinical
323		outcomes;
324		
325	IV.A.1.c).(1).(s)	the role of national and international agencies in
326		toxicology; and,
327		
328	IV.A.1.c).(1).(t)	administrative aspects of the practice of medical
329		toxicology.
330		
331	IV.A.1.d)	Practice-Based Learning and Improvement
332		
333	IV.A.1.d).(1)	Fellows must demonstrate the ability to investigate and evaluate their
334		care of patients, to appraise and assimilate scientific evidence, and to
335		continuously improve patient care based on constant self-evaluation
336		and lifelong learning.
337	IV.A.1.e)	Interpersonal and Communication Skills
338		
339	IV.A.1.e).(1)	Fellows must demonstrate interpersonal and communication
340		skills that result in the effective exchange of information and
341		collaboration with patients, patients' families, and health
342		professionals.
343		
344	IV.A.1.f)	Systems-Based Practice
345		
346	IV.A.1.f).(1)	Fellows must demonstrate an awareness of and
347		responsiveness to the larger context and system of health care,
348		including the social determinates of health, as well as the ability
349		to call effectively on other resources in the system to produce
350		optimal care.
351		
352	<b>IV.B.</b>	<b>Regularly Scheduled Educational Activities</b>
353		
354	IV.B.1.	There must be at least four hours per week of planned didactic experiences
355		focused on medical toxicology.
356		
357	IV.B.1.a)	All planned didactic experiences must be supervised by faculty
358		members.
359		
360	IV.B.2.	Fellows must attend required seminars, conferences, and journal clubs.

- 361  
362 IV.B.3. Fellows must actively participate in the planning and delivery of didactic  
363 sessions.  
364  
365 IV.B.4. The program must ensure that fellows assigned to participating sites will  
366 participate in required conferences and other didactic activities at the primary  
367 clinical site.  
368  
369 IV.B.4.a) The majority of didactic sessions should take place at the primary  
370 clinical site.  
371  
372 IV.B.5. Fellows must have instruction in the principles of hyperbaric medicine.  
373  
374 IV.B.6. Planned didactic experiences should include presentations based on the  
375 defined curriculum and should include morbidity and mortality conferences,  
376 journal review, administrative seminars, and conferences on research methods.  
377  
378 IV.B.6.a) All planned didactic experiences should have an evaluative component  
379 to measure fellow participation and educational effectiveness, including  
380 faculty-fellow interaction.  
381  
382 **IV.C. Clinical Experiences**  
383  
384 IV.C.1. Clinical experiences must be structured to allow fellows to function as a part of  
385 an effective interprofessional team that works together toward the shared goals  
386 of patient safety and quality improvement.  
387  
388 IV.C.2. Fellows must have a minimum of 12 months in a 24-month program and 18  
389 months in a 36-month program of clinical experience as the primary or consulting  
390 physician responsible for providing direct/bedside patient evaluation,  
391 management, screening, and preventive services.  
392  
393 IV.C.3. Fellows must have experience with a referral population of poisoned patients  
394 under the supervision of a physician who is a medical toxicologist for the duration  
395 of the program.  
396  
397 IV.C.4. Fellows must have experience in a local or regional poison center or a regional  
398 referral toxicology service that annually takes at least 1,500 calls requiring  
399 physician telephone consultation or intervention.  
400  
401 IV.C.4.a) Each fellow must consult on an average of 240 patient encounters per  
402 year through referral calls involving poisoned patients.  
403  
404 IV.C.5. Fellows without prior experience in adult and pediatric critical care must have  
405 clinical experiences of at least one month in an adult intensive care unit and one  
406 month in a pediatric intensive care unit.  
407  
408 IV.C.6. Programs must provide fellows with a broad education, including in the basic  
409 skills and knowledge of medical toxicology, so that they may function as  
410 specialists competent in providing comprehensive patient care in medical  
411 toxicology, research, and teaching.  
412

413	IV.C.7.	The curriculum must include the following medical toxicology core content areas:
414		
415	IV.C.7.a)	analytical and forensic toxicology;
416		
417	IV.C.7.b)	assessment and population health;
418		
419	IV.C.7.c)	clinical assessment;
420		
421	IV.C.7.d)	principles of toxicology;
422		
423	IV.C.7.e)	therapeutics; and,
424		
425	IV.C.7.f)	toxins and toxicants.
426		
427	IV.C.8.	Fellows must have patient experience with a heterogeneous clinical spectrum of diagnoses, for patients broadly representative of society in the country or jurisdiction in which the program operates.
428		
429		
430		
431	IV.C.8.a)	Fellows must have patient experiences with diagnoses resulting from patient exposure to:
432		
433		
434	IV.C.8.a).(i)	drugs;
435		
436	IV.C.8.a).(ii)	industrial, household, and environmental toxicants;
437		
438	IV.C.8.a).(iii)	natural products; and,
439		
440	IV.C.8.a).(iv)	other xenobiotics.
441		
442	IV.C.8.b)	Each fellow must evaluate and manage at least 25 patients with acute or chronic workplace occupational and environmental exposures over the course of the educational program.
443		
444		
445		
446	IV.C.8.b).(i)	These patients must be seen in an occupational medicine or toxicology clinic, or as occupational medicine patients in a referral setting.
447		
448		
449		
450	IV.C.8.c)	Each fellow must provide care for at least 200 acutely poisoned patients over the course of the program.
451		
452		
453	IV.C.8.c).(i).	These patients must represent all age groups and populations.
454		
455	IV.C.8.c).(ii)	At least 10 percent of acutely poisoned patients should be children.
456		
457		
458	IV.C.9.	Fellows must have experience in evaluating and managing patients with workplace and environmental exposures and must have experience in workplace evaluation, as well as in an occupational medicine or toxicology clinic.
459		
460		
461		
462	IV.C.10.	Fellows must be provided opportunities to teach and participate in undergraduate, graduate, and continuing education activities.
463		
464		

465	IV.C.11.	Fellows must document required patient care experiences.
466		
467	IV.C.12.	Fellows should have experience in hyperbaric oxygen therapy as available in the
468		country or jurisdiction.
469		
470	<b>IV.C.</b>	<b>Scholarly Activity</b>
471		
472	IV.D.1.	Fellows' Scholarly Activity
473		
474	IV.D.1.a)	The curriculum must advance fellows' knowledge of the basic principles
475		of research, including how research is conducted, evaluated, explained
476		to patients, and applied to patient care.
477		
478	IV.D.1.b)	Fellows must participate in research or scholarly activity that includes at
479		least one of the following:
480		
481	IV.D.1.a).(i)	peer-reviewed funding and research;
482		
483	IV.D.1.a).(ii)	publication of original research or review articles; or,
484		
485	IV.D.1.a).(iii)	presentations at local regional, or national professional and
486		scientific society meetings.
487		
488	IV.D.1. b)	Fellows must complete a scholarly project prior to graduation.
489		
490	IV.D.2.	Faculty Scholarly Activity
491		
492	IV.D.2.a)	All core faculty members must demonstrate significant contributions to
493		the subspecialty of medical toxicology through scholarly activity.
494		
495	IV.D.2.b)	Each core physician faculty member must demonstrate at least one
496		piece of scholarly activity per year, averaged over the past five years.
497		
498	<b>V.</b>	<b>Evaluation</b>
499		
500	<b>V.A.</b>	<b>Fellow Evaluation</b>
501		
502	V.A.1.	Assessment of procedural competence should include a formal evaluation
503		process and not be based solely on a minimum number of procedures
504		performed.
505		
506	<b>V.B.</b>	<b>Clinical Competency Committee</b>
507		
508		See International Foundational Requirements, Section V.B.
509		
510	<b>V.C.</b>	<b>Faculty Evaluation</b>
511		
512		See International Foundational Requirements, Section V.C.
513		
514	<b>V.D.</b>	<b>Program evaluation and Improvement</b>
515		
516		See International Foundational Requirements, Section V.D.

517		
518	<b>V.E.</b>	<b>Program evaluation Committee</b>
519		
520		See International Foundational Requirements, Section V.E.
521		
522	<b>VI.</b>	<b>The Learning and Working Environment</b>
523		
524	<b>VI.A.</b>	<b>Principles</b>
525		
526		See International Foundational Requirements, Section VI.A.
527		
528	<b>VI.B.</b>	<b>Patient Safety</b>
529		
530		See International Foundational Requirements, Section VI.B.
531		
532	<b>VI.C.</b>	<b>Quality Improvement</b>
533		
534		See International Foundational Requirements, Section VI.C.
535		
536	<b>VI.D.</b>	<b>Supervision and Accountability</b>
537		
538	VI.D.1.	The program must have clear guidelines that delineate which Competencies
539		must be met to determine when a fellow can progress to be supervised
540		indirectly.
541		
542	<b>VI.E.</b>	<b>Professionalism</b>
543		
544		See International Foundational Requirements, Section VI.E.
545		
546	<b>VI.F.</b>	<b>Well-Being</b>
547		
548		See International Foundational Requirements, Section VI.F.
549		
550	<b>VI.G.</b>	<b>Fatigue</b>
551		
552		See International Foundational Requirements, Section VI.G.
553		
554	<b>VI.H.</b>	<b>Transitions of Care</b>
555		
556		See International Foundational Requirements, Section VI.H.
557		
558	<b>VI.I.</b>	<b>Clinical Experience and Education</b>
559		
560		See International Foundational Requirements, Section VI.I.
561		
562	<b>VI.J.</b>	<b>On-Call Activities</b>
563		
564		See International Foundational Requirements, Section VI.J.